检索结果-南通市图书馆

Combination therapy of dabrafenib plus trametinib in patients with BRAF^(V600E)-mutated biliary tract cancer

Hepatobiliary & Pancreatic Diseases International 2021年第5期20卷 506-507页

作者： Alessandro Rizzo angela dalia ricci Giovanni Brandi Division of Oncology Azienda Ospedaliero-Universitaria di Bolognavia Albertoni 15BolognaItaly

To the Editor: In the last decade, next-generation sequencing(NGS)-based molecular profiling has shed light on the molecular landscape of biliary tract cancer(BTC), revealing the presence of several potentially actionable mutations [1]. According to Clinical ***, there are at least 40 phase I to IV ongoing trials aimed at evaluating the role of targeted treatments in BTC, as monotherapy or in combination with other anticancer agents [2]. Early encouraging results have been observed with therapies targeting IDH mutations, FGFR fusions, HER family and, more recently, BRAF mutations [3].

关键词： BRAF cancer Clinical

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?

引用

Cancer Communications 2020年第9期40卷 461-464页

作者： Giovanni Brandi angela dalia ricci Alessandro Rizzo Chiara Zanfi Simona Tavolari Andrea Palloni Stefania De Lorenzo Matteo Ravaioli Matteo Cescon Department of Experimental Diagnostic and Specialty MedicineS.Orsola-Malpighi University HospitalBologna 40138Italy Department of General Surgery and Transplantation S.Orsola-Malpighi University HospitalBologna 40138Italy Center of Applied Biomedical Research S.Orsola-Malpighi University HospitalBologna 40138Italy

Dear Editor:In the last two decades,the indications of liver transplantation(LT)for primary and secondary hepatobiliary malignancies have been increasingly *** this attractive option still represents the“last court of appeal”in cancer patients,the role of LT is well established in hepatocellular carcinoma(HCC),where transplantation has also demonstrated a benefit for selected patients affected by peri-hilar cholangiocarcinoma,intrahepatic cholangiocarcinoma,and neuroendocrine tumors[1].Recently,the interest in LT in liver-limited stage IV colorectal cancer(CRC)has increased due to recent advances in transplantation techniques that have led to a re-evaluation of this approach.

关键词： colorectal cancer liver

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report

引用

World Journal of Gastrointestinal Oncology 2020年第12期12卷 1456-1463页

作者： Mariacristina Di Marco Riccardo Carloni Stefania De Lorenzo Cristina Mosconi Andrea Palloni Elisa Grassi Daria Maria Filippini angela dalia ricci Alessandro Rizzo Alessandro Di Federico Donatella Santini Daniela Turchetti Claudio ricci Carlo Ingaldi Laura Alberici Francesco Minni Rita Golfieri Giovanni Brandi Riccardo Casadei Department of Experimental Diagnosticand Specialty Medicine-DIMESSant'Orsola-Malpighi HospitalUniversity of BolognaBologna 40138Italy Division of Oncology Azienda Ospedaliero-Universitaria di BolognaBologna 40138Italy Radiology Unit Department of Diagnostic Medicine and PreventionSant'Orsola-Malpighi HospitalUniversity of BolognaBologna 40138Italy Medical Oncology Ospedale Degli InfermiFaenza 48018Italy Pathology Unit Sant'Orsola-Malpighi HospitalBologna 40138Italy Unit of Medical Genetics Sant'Orsola-Malpighi HospitalUniversity of BolognaBologna 40138Italy Division of Pancreatic Surgery Azienda Ospedaliero-Universitaria Di BolognaBologna 40138Italy Department of Internal Medicine and Surgery Alma Mater StudiorumUniversity of BolognaBologna 40138Italy

BACKGROUND Pancreatic mucinous cystadenocarcinoma(MCAC)is a rare malignancy with a poor prognosis when it presents metastases at *** to its very low incidence,there are no clear recommendations for the treatment of advanced ***(an oral PARP inhibitor)has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline BRCA1/2 ***,we report the first case of a germline BRCA1 mutated unresectable MCAC which was effectively treated with *** SUMMARY A 41-year-old woman,without personal or family history of cancer,was diagnosed with ovarian and peritoneal metastases of *** underwent 12 cycles of gemcitabine plus oxaliplatin(GEMOX)obtaining a partial response and allowing radical *** year later,local recurrence was documented,and other 12 cycles of GEMOX were administered obtaining a complete *** years later,another local recurrence,not amenable to surgical resection,was *** started FOLFIRINOX(oxaliplatin,irinotecan,leucovorin and fluorouracil),obtaining a partial response after 8 *** the excellent response to platinum-based chemotherapy,BRCA testing was performed,and a BRCA1 germline mutation was *** was switched to maintenance olaparib due to chemotherapy-related toxicities and achieved an almost complete metabolic response,with a reduction in the diameter of the lesion,after three months of *** The current case suggests the beneficial effect of olaparib in BRCA mutated ***,further studies are required.

关键词： Mucinous cystadenocarcinoma Pancreatic cancer BRCA1 gene Olaparib Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Prognostic Value of Cardiopulmonary Exercise Test in Elderly Women with Heart Failure and Reduced or Preserved Ejection Fraction

引用

World Journal of Cardiovascular Diseases 2014年第7期4卷 341-349页

作者： angela Beatrice Scardovi Renata De Maria Alessandro Ferraironi Marco Renzi Franco Turi Marina Parolini Tiziana Di Giacomo Roberto ricci Cardiology Department S. Spirito Hospital Rome Italy CNR Clinical Physiology Institute Cardio Thoracic and Vascular Department Niguarda Hospital Milan Italy

The prognostic role of cardiopulmonary exercise test (CPET) in elderly women with chronic heart failure (HF) has not yet been clarified. We assessed the incremental value of CPET variables for risk stratification in female HF patients with preserved or reduced left ventricular ejection fraction (LVEF). We prospectively followed up 131 female HF outpatients aged 72 [interquartile range 62 - 77] years after a symptom limited CPET. 34% had ischemic heart disease and 14% permanent atrial fibrillation, 24% were in NYHA class III. LVEF was 50% [interquartile range 36 - 62], peak oxygen consumption was 11.3 [interquartile range 9.2 - 13.5] ml/kg/min;the slope of the regression line relating ventilation to CO2 output was 33.9 [interquartile range 30.3 - 44.9];40% of patients showed exercise oscillatory breathing during CPET. During a median follow-up of 18 months [interquartile range 8 - 54], overall 39 patients (29.7%) met the combined end-point of cardiovascular mortality or HF admission using a time-to-first event approach. Moderate to severe mitral regurgitation, slope, exercise oscillatory breathing were independently associated to cardiovascular mortality or HF admission. When CPET ventilatory variables were added to clinical and echocardiographic parameters, prediction of the combined point improved significantly (AUC 0.755 (95% CI 0.662 to 0.832) vs 0.634 (95% CI 0.536 to 0.725), p = 0.016). In conclusion, among elderly female HF patients the CPET derived parameters EOB and VE/VCO2 slope emerged as strong prognostic markers, with additive predictive value to clinical and echocardiographic parameters in patients with both reduced and preserved LVEF.

关键词： Women Heart Failure Cardiopulmonary Exercise Test Ventilatory Inefficiency

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer

引用

Science China(Life Sciences) 2022年第11期65卷 2205-2217页

作者： Chang Gong Ziliang Cheng Yaping Yang Jun Shen Yingying Zhu Li Ling Wanyi Lin Zhigang Yu Zhihua Li Weige Tan Chushan Zheng Wenbo Zheng Jiajie Zhong Xiang Zhang Yunjie Zeng Qiang Liu RStephanie Huang Andrzej LKomorowski Eddy SYang François Bertucci Francesco ricci Armando Orlandi Gianluca Franceschini Kazuaki Takabe Suzanne Klimberg Naohiro Ishii angela Toss Mona PTan Mathew A Cherian Erwei Song Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong-Hong Kong Joint Laboratory for RNA MedicineBreast Tumor CenterSun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Department of Radiology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Clinical Research Design Division Clinical Research CenterSun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Department of Medical Statistics School of Public HealthSun Yat-sen UniversityGuangzhou 510080China Department of Breast Surgery the Second Affiliated HospitalShandong UniversityJinan 250033China Department of Breast Surgery Key Laboratory of Breast DiseasesThird Hospital of NanchangNanchang 330009China Department of Breast Surgery the First Affiliated HospitalGuangzhou Medical UniversityGuangzhou 510120China Department of Pathology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Department of Experimental and Clinical Pharmacology University of MinnesotaMinneapolisMN 55455USA Department of Surgery College of MedicineUniversity of RzeszówRzeszów 35-959Poland Department of Radiation Oncology O’Neal Comprehensive Cancer CenterUniversity of Alabama at Birmingham School of MedicineBirminghamALUSA Laboratoty of Predictive Oncology Institut Paoli-CalmettesCentre de Recherche en Cancérologie de MarseilleINSERM UMR1068CNRS UMR725MarseilleFrance Department of Drug Development and Innovation(D3i) Institut CurieParis 75005France Comprehensive Cancer Center UOC di Oncologia MedicaFondazione Policlinico Universitario A.Gemelli IRCCSRome 00168Italy Multidisciplinary Breast Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversitàCattolica del Sacro CuoreRome 00168Italy Breast Surgery Department of Surgical OncologyRoswell Park Comprehensive Cancer CenterBuffaloNYUSA Department of Surgery MD Anderson Cancer CenterHoustonTX 77030USA Department of Plastic and Reconstructive Surgery

Patients with hormone receptor(HR)-positive tumors breast cancer usually experience a relatively low pathological complete response(p CR)to neoadjuvant chemotherapy(NAC).Here,we derived a 10-micro RNA risk score(10-mi RNA RS)-based model with better performance in the prediction of p CR and validated its relation with the disease-free survival(DFS)in 755 HRpositive breast cancer patients(273,265,and 217 in the training,internal,and external validation sets,respectively).This model,presented as a nomogram,included four parameters:the 10-mi RNA RS found in our previous study,progesterone receptor(PR),human epidermal growth factor receptor 2(HER2)status,and volume transfer constant(K).Favorable calibration and discrimination of 10-mi RNA RS-based model with areas under the curve(AUC)of 0.865,0.811,and 0.804 were shown in the training,internal,and external validation sets,*** who have higher nomogram score(>92.2)with NAC treatment would have longer DFS(hazard ratio=0.57;95%CI:0.39–0.83;P=0.004).In summary,our data showed the 10-mi RNA RS-based model could precisely identify more patients who can attain p CR to NAC,which may help clinicians formulate the personalized initial treatment strategy and consequently achieves better clinical prognosis for patients with HRpositive breast cancer.

关键词： hormone receptor-positive breast cancer micro RNA signature neoadjuvant chemotherapy dynamic contrast-enhanced magnetic resonance imaging nomogram

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：